Littenberg Benjamin, MacLean Charles D
Division of General Internal Medicine, University of Vermont College of Medicine, Burlington, VT 05401, USA.
J Gen Intern Med. 2006 Mar;21(3):207-11. doi: 10.1111/j.1525-1497.2006.00339.x.
Federal laws and regulations, including the Health Insurance Portability and Accountability Act (HIPAA) of 1996, intended primarily to protect individuals, have been described as significant barriers to the use of clinical registries and other population-based tools for health care research. Although these regulations allow for the waiver or alteration of usual consent procedures when the research meets certain specific criteria, waivers and alterations are rarely used in health care research.
The Vermont Diabetes Information System is a multistate randomized trial of a quality improvement intervention that uses a novel alteration of informed consent to help ensure that the study sample is representative of the target population. Patients are notified by mail that they are eligible for the study and that they may opt out of the study, if they desire, by calling a toll-free number.
Seven thousand five hundred and fifty-eight patients were invited to participate. Two hundred and ten (2.8%) opted out. Three patients (0.04%) filed complaints, all of which were addressed satisfactorily.
Health Insurance Portability and Accountability Act and other federal regulations raise challenges to the use of clinical registries in research, but modifications to the consent process, including passive consent methods, are useful tools to overcome these challenges. It is possible to recruit a broad and representative population under current law while maintaining appropriate protections for research subjects.
包括1996年《健康保险流通与责任法案》(HIPAA)在内的联邦法律法规主要旨在保护个人,但已被视为使用临床登记系统和其他基于人群的医疗保健研究工具的重大障碍。尽管这些法规允许在研究符合某些特定标准时放弃或变更通常的同意程序,但在医疗保健研究中很少使用豁免和变更。
佛蒙特州糖尿病信息系统是一项多州随机试验,是一种质量改进干预措施,采用了一种新颖的知情同意变更方式,以帮助确保研究样本代表目标人群。通过邮件通知患者他们有资格参加研究,如果他们愿意,可以拨打免费电话退出研究。
邀请了7558名患者参与。210名(2.8%)选择退出。3名患者(0.04%)提出投诉,所有投诉均得到满意解决。
《健康保险流通与责任法案》和其他联邦法规给研究中使用临床登记系统带来了挑战,但对同意程序的修改,包括被动同意方法,是克服这些挑战的有用工具。在现行法律下,有可能招募广泛且具有代表性的人群,同时为研究对象提供适当保护。